Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034
December 21 2020 - 9:15AM
Business Wire
Patents and patent application provide
additional coverage for company’s therapeutic for patients with
advanced solid tumors
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, today announced that the U.S. Patent and Trademark
Office has issued two new patents, No.10,792,251 (the ‘251 patent)
and No. 10,837,018 (the ‘018 patent), and allowed U.S. patent
application 14/907,430 (the ‘430 application), further
strengthening the Company’s intellectual property position and
coverage for the Company’s therapeutic product candidate,
cavrotolimod.
The ‘018 patent and the ‘430 application, both titled,
“Spherical Nucleic Acid-based Constructs as Immunostimulatory
Agents for Prophylactic and Therapeutic Use,” covers nanoparticles
with a corona of CpG oligonucleotides and their methods for
treating cancer.
The ‘251 patent, jointly owned by the Company and Northwestern
University, titled, “Liposomal Particles, Methods of Making Same
and Uses Thereof,” is directed to liposomal nanoparticles with
toll-like receptor 9 (TLR9) agonist oligonucleotides and methods
for treating cancer.
“The two issued patents and the soon-to-be-issued patent
demonstrate our commitment to developing cavrotolimod, which is
currently in a Phase 2 clinical trial for the potential treatment
of Merkel cell carcinoma and cutaneous squamous cell carcinoma,”
said David Giljohann, Chief Executive Officer of Exicure. “We are
pleased with cavrotolimod’s development to date and excited about
its potential to address unmet need for patients living with these
rare forms of skin cancers.”
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for neurology, immuno-oncology,
inflammatory diseases and other genetic disorders based on our
proprietary Spherical Nucleic Acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN an
SNA–based therapeutic candidate, for the treatment of Friedreich’s
ataxia (FA). Exicure's drug candidate AST-008 is currently in a
Phase 1b/2 clinical trial in patients with advanced solid tumors.
Exicure is in Chicago, IL and has an office in Cambridge, MA.
For more information, visit Exicure’s website at
www.exicuretx.com.
Exicure Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements in this press release other than statements of
historical fact could be deemed forward looking including, but not
limited to, statements regarding the company’s intellectual
property portfolio. The forward-looking statements in this press
release speak only as of the date of this press release, and the
company undertakes no obligation to update these forward-looking
statements. Forward-looking statements are based on management’s
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those contained in any
forward-looking statement as a result of various factors,
including, without limitation: the risks that the ongoing COVID-19
pandemic may disrupt the company’s business and/or the global
healthcare system more severely than it has to date or more
severely than anticipated, which may have the effect of impacting
or delaying the company’s ongoing Phase 1b/2 clinical trial;
unexpected costs, charges or expenses that reduce the company’s
capital resources; the company’s preclinical or clinical programs
do not advance or result in approved products on a timely or cost
effective basis or at all; the results of early clinical trials are
not always being predictive of future results; the cost, timing and
results of clinical trials; that many drug candidates do not become
approved drugs on a timely or cost effective basis or at all; the
ability to enroll patients in clinical trials; possible safety and
efficacy concerns; regulatory developments; risks that preliminary
results from clinical trials are not necessarily predictive of
future clinical trial results; and the ability of the company to
protect its intellectual property rights. For a discussion of other
risks and uncertainties, and other important factors, any of which
could cause the company’s actual results to differ from those
contained in the forward-looking statements, see the section titled
“Risk Factors” in the company’s Quarterly Report on Form 10-Q, as
updated by the company’s subsequent filings with the Securities and
Exchange Commission. All information in this press release is as of
the date of the release, and the company undertakes no duty to
update this information, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201221005412/en/
For Media: Karen Sharma MacDougall 781-235-3060
ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024